GENE ONLINE|News &
Opinion
Blog

2018-11-22| PartnerAsia-Pacific

Med X Tech Summit Asia (MEDTEX) 2018 – Overview of Day 1 Program

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

Proudly co-organized by GeneOnline, the global biotech conference brings key opinion leaders comprising healthcare professionals and technology giants under one roof promoting scientific exchange and business partnerships. The event is to be held from Nov 29 – 30, 2018 at the Grande Luxe Banquet, Taipei, Taiwan.

This year, Taipei will bag the honor of hosting MEDTEX 2018, a showcase event displaying the digital revolution in the healthcare industry. This event is as an ideal opportunity to witness the latest advances in next generation bio-therapeutics and breakthroughs in precision medicine. MEDTEX will serve as the focal point where cutting-edge research and technology meet business perspectives. Expert talks will be delivered on various hot topics encompassing AIoT, Immune-Oncology, Blockchain, Big data, Gene editing and Cell therapy among others.

The following are some of the major highlights on the first day of the conference.

The guests will be welcomed with opening remarks from two honorary figures, Mr. Jia-Chyuan Su, President, Legislative Yuan (R.O.C) and Dr. Chi-Huey Wong, Distinguished Research Fellow at Academia Sinica.

1) The global healthcare industry is constantly evolving with the advent of new technologies and collaborative participation of many international players. Therefore, the inaugural program of the session is titled CEO Perspectives where a panel of distinguished speakers from various premier industries would discuss on the topic “Foreseeing the Future of Healthcare – Cross-industry Opportunities and Challenges of Healthcare Advances”. The goal is to garner key insights on cross-industry cooperation opportunities, challenges and strategies. The discussion will be moderated by Simon Chang, the Chairman of IBMI. The key members of the panel include Murakami Sei (Hitachi), Birgit Reitmaier (Merck), Larry Merizalde (Teva), Eunice Chiu (NVIDIA) and Harry Yang (Qisda).

2) The second panel discussion would focus on the new breakthroughs in the rapidly advancing fields of Immuno-oncology, Next generation Biotherapeutics and Gene editing. The discussion will be moderated by Clifford Chao, Vice President of the China Medical University. The speakers in the panel include Seigo Izumo (Takeda Pharma), Wise Young (StemCyte), David DiGiusto (Semma Therapeutics) and Tony J.C. Wang, (Columbia University Medical Center). The discussion also includes fireside chats from Trevor Martin (Mammoth Biosciences) and Chris Shu (Pacific 8 Ventures).

3) The final discussion session on the first day is titled Delivering Personalized Healthcare through Precision Medicine. The discussion will be moderated by Yun Yen, the Chair Professor of Taipei Medical University. The speakers in the panel include Alireza Haghighi (Harvard Medical School), Colin Collins (Vancouver Prostate Centre) and Liang-Yeu Lenny Chen (IBM Watson Health).

Interesting talks and discussions are also scheduled for the second day of the event. Follow GeneOnline for more details.

To register for the event, please visit

https://www.eventbrite.com/e/medtex-med-x-tech-summit-asia-2018-tickets-50897919046

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Merck Strikes $50 Million Deal with ModeX For Rights to EBV Vaccine
2023-03-08
Exciting Cell & Gene Therapy Research Updates in Glaucoma and Nerve Regeneration
2023-03-08
Developments in Regenerative Medicine: Gene Delivery Tools and Cell Therapy for Parkinson’s Disease
2023-03-08
LATEST
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Amgen Faces Class Action Lawsuit for Concealing $10.7 Billion Tax Bill to Manipulate Stock Price
2023-03-16
ImmunoPrecise Antibodies, Libera Bio Ink $155 Million Pact To Deliver Antibodies With Nanotechnology
2023-03-16
Dermavant Eyes Second Vtama Indication with Topline Atopic Dermatitis Results
2023-03-15
Scroll to Top